Dr. Xiangfei "Scott" Cheng is the Founder and CEO of Allphild Inc.  He is the sole inventor of hundreds of innovative molecules filed in U.S. patent applications. His inventions target cancers, autoimmune diseases, traumatic brain injury (TBI), neurodegenerative disorders, immunomodulation, transplant immune tolerance and lung fibrosis, and include platforms in microRNA (miRNA)-based therapy, synergistic approach combining CAR-T therapy with the novel molecule that modulates gene expression to prevent CAR-T cell exhaustion,  immunotherapy, cell therapy,  gene therapy,  and more. 

Additionally, he is the sole inventor of several U.S. patent-pending artificial intelligence (AI) technologies for drug development, clinical development, and healthcare, as well as an AI-powered device designed to assist individuals with disabilities.    

He holds both an M.D. and a Ph.D.  Prior to founding Allphild Inc, he was Senior Vice President (SVP) of Translational Medicine at a small to mid-sized biopharmaceutical company. He also held leadership positions at Thermo Fisher Scientific, a global leader in biotechnology, where he oversaw cross-functional teams across multiple sites, driving initiatives in Immunology, Molecular Biology, and Clinical Development. 

Before joining Thermo Fisher Scientific, Dr. Cheng held a faculty role at University of Maryland School of Medicine, driving research in immunomodulation and immune tolerance for transplantation, within a division internationally recognized under the leadership of a former President of International Xenotransplantation Association and current Harvard University Professor. He was also actively involved in cancer research in Greenebaum Comprehensive Cancer Center at the same university. With over 25 years of experience in R&D, preclinical study, translational medicine, clinical studies and drug development in various areas, Dr. Cheng has authored more than 90 publications.

Dr. Cheng specialized in postdoctoral research in Biochemistry and Molecular Biology at Northwestern University, Chicago, USA, under the mentorship of a late member of the National Academy of Sciences (NAS) and additionally in Biochemistry at Umeå University in Sweden. His Ph.D. in Biochemistry was awarded by Umeå University, and M.D was awarded by Nanchang University Medical School.